Market News AIOpen the app

Wall Street analysts changed their ratings and price targets for Ionis Pharmaceuticals.

OpinionRead the original at moomoo.com
Neutral

Several analysts kept buy ratings on Ionis, but Morgan Stanley and TD Cowen lowered their price targets. These differing opinions report no change to Ionis’s business, so they leave its outlook unchanged.

IONS · Ionis Pharmaceuticals

AI read · Neutral

The AI's read

These notes change analysts’ views, not Ionis’s reported business results. Barclays, Wells Fargo, and BMO kept buy ratings, but Morgan Stanley and TD Cowen lowered their targets. With no new company results here, these opinions point in different directions.

Get alerts for IONS

Follow Ionis Pharmaceuticals (IONS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IONS
Free on the App Store and Google Play, or on the web.